VCM
SRPT icon

Vigilant Capital Management’s Sarepta Therapeutics SRPT Stock Holding History

Vigilant Capital Management’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-70
Closed -$6K – 642
2021
Q4 		$6K Hold
70
– – ﹤0.01% 562
2021
Q3 		$6K Hold
70
– – ﹤0.01% 626
2021
Q2 		$5K Hold
70
– – ﹤0.01% 395
2021
Q1 		$5K Hold
70
– – ﹤0.01% 341
2020
Q4 		$12K Hold
70
– – ﹤0.01% 293
2020
Q3 		$10K Hold
70
– – ﹤0.01% 313
2020
Q2 		$11K Hold
70
– – ﹤0.01% 278
2020
Q1 		$7K Hold
70
– – ﹤0.01% 298
2019
Q4 		$9K Hold
70
– – ﹤0.01% 427
2019
Q3 		$5K Buy
+70
New +$8.27K ﹤0.01% 363

Other funds holding SRPT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vigilant Capital Management's SRPT Position: Q1 2022 in Review

Vigilant Capital Management sold out of Sarepta Therapeutics (SRPT) in Q1 2022, closing a stake of 70 shares — an estimated $6K sold.

Vigilant Capital Management first reported a position in SRPT in Q3 2019 and held it in 10 quarters. The position peaked at $12K in Q4 2020. 328 funds tracked by Wall St. Rank hold SRPT as of Q1 2022.

  • Vigilant Capital Management reported no remaining Sarepta Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Vigilant Capital Management sold 70 Sarepta Therapeutics shares in Q1 2022, an estimated $6K.
  • Vigilant Capital Management first reported a position in Sarepta Therapeutics in Q3 2019 and held it in 10 quarters.
  • Vigilant Capital Management's Sarepta Therapeutics position peaked at $12K in Q4 2020.
  • 328 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2022.

Based on Vigilant Capital Management's 13F filing for Q1 2022, filed 7 Apr 2022.